Bevacizumab biosimilar - Synermore Biologics

Alternative Names: SYN-050

Latest Information Update: 15 Oct 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Synermore Biologics
Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

15 Oct 2024 Bevacizumab biosimilar is still in phase I trials for Cancer in Taiwan (Synermore Pipeline, October 2024)
28 Feb 2024 No recent reports of development identified for phase-I development in Cancer in Taiwan (Parenteral)
20 Jan 2021 Phase-I clinical trials in Cancer in Taiwan (Parenteral) (Synermore Biologics pipeline, January 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com